1

2

3

4

5

6
Dixon Julie, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia, Lee Wendy, Sibley Robert, Bear Brian, Chandler Brent, Miranda Karl, Chen Gang, Chen Zhi, Brittelli David, Clark Roger B: 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors. Bayer Pharmaceuticals Corporation, Dixon Julie, Dumas Jacques, Brennan Catherine, Hatoum Mokdad Holia, Lee Wendy, Sibley Robert, Bear Brian, Chandler Brent, Miranda Karl, Chen Gang, Chen Zhi, Brittelli David, Clark Roger B, GREENMAN Jeffrey M, April 3, 2003: WO/2003/026666 (3 worldwide citation)

The invention provides novel substituted 2,4-diaminopyrimidine compounds (I), in which L is a linker selected from: -O-(CH¿2?)¿1-4?- ; s(O)¿0-2?-(CH¿2?)¿1-4?- ; -N(R?1¿)-(CH¿2?)¿1-4?-(CH¿2?)¿1-4?-O-(CH¿2?)¿1-4?- ; -N(R?1¿)-C(O)-(CH¿2?)¿1-4?- ; (I) and (I) G represents: Alternatively, L may represent ...


7
Smith Roger, Dumas Jacques, Wang Gan, Lee Wendy, Miranda Karl: Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders. Bayer Healthcare, Smith Roger, Dumas Jacques, Wang Gan, Lee Wendy, Miranda Karl, TRAVERSO Richard J, July 5, 2007: WO/2007/075650

Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A= pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions ...